A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Status:
RECRUITING
Trial end date:
2028-08-23
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates.
Phase:
PHASE2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute